Compartmental pharmacokinetics of the antifungal echinocandin caspofungin (MK-0991) in rabbits

Antimicrobial Agents and Chemotherapy

Volumn 45, Issue 2, 2001, Pages 596-600

  Groll, A H ^a   Gullick, B M ^a   Petraitiene, R ^a   Petraitis, V ^a   Candelario, M ^a   Piscitelli, S C ^a   Walsh, T J ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIFUNGAL AGENT; CASPOFUNGIN;

ANIMAL EXPERIMENT; ANTIFUNGAL ACTIVITY; AREA UNDER THE CURVE; ARTICLE; BODY WEIGHT; COMPARTMENT MODEL; CONTROLLED STUDY; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG HALF LIFE; DRUG TOLERABILITY; FEMALE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; OPPORTUNISTIC INFECTION; PRIORITY JOURNAL; RABBIT; STEADY STATE;

EID: 0035144963     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/AAC.45.2.596-600.2001     Document Type: Article

References (23)

1. Evaluation of the echinocandin antifungal MK-0991 (L-743, 872): Efficacies in mouse models of disseminated aspergillosis, candidiasis, and cryptococcosis
2. In vitro evaluation of the pneumocandin antifungal agent L-733560, a new water-soluble hybrid of L-705589 and L-731373
3. In vitro preclinical evaluation studies with the echinocandin antifungal MK-0991 (L-743, 872)
4. Guide for the care and use of laboratory animals
5. Adapt II user's guide
6. In vitro antifungal activity of pneumocandin L-743,872 against a variety of clinically important molds
7. In vitro pharmacodynamic properties of MK-0991 determined by time-kill methods
8. Comparison of in vitro activities of the new triazole SCH56592 and the echinocandins MK-0991 (L-743,872) and LY303366 against opportunistic filamentous and dimorphic fungi and yeasts
9. Pneumocandin L-743,872 enhances the activities of amphotericin B and fluconazole against Cryptococcus neoformans in vitro
10. Treatment of murine disseminated candidiasis with L-743,872
11. MK-0991
12. Preliminary animal pharmacokinetics of the parenteral antifungal agent MK-0991 (L-743,872)
13. Lipopeptide inhibitors of fungal glucan synthase
14. Cilofungin (LY121019) shows nonlinear plasma pharmacokinetics and tissue penetration in rabbits
15. Activity of MK-0991 (L-743,872), a new echinocandin, compared with those of LY303366 and four other antifungal agents tested against blood stream isolates of Candida spp.
16. In vitro growth-inhibitory activity of pneumocandins L-733,560 and L-743,872 against putatively amphotericin B. and fluconazole-resistant Candida isolates: Influence of assay conditions
17. Antifungal efficacy, safety, and single-dose pharmacokinetics of LY30366, a novel echinocandin, in experimental disseminated candidiasis in persistently neutropenic rabbits
18. Efficacy of LY-303366 against invasive pulmonary aspergillosis
19. Efficacy of MK-991 (L-743,872), a semisynthetic pneumocandin, in murine models of Pneumocystis carinii
20. In vitro activity of a new pneumocandin antifungal, L-743,872, against azole-susceptible and -resistant Candida species
21. Chronic silastic central venous catheterization for induction, maintenance, and support of persistent granulocytopenia in rabbits
22. Antifungal effects of the nonlinear pharmacokinetics of cilofungin, a 1, 3-β-glucan synthetase inhibitor, during continuous and intermittent intravenous infusions in treatment of experimental disseminated candidiasis
23. Application of Akaike's information criterion in the evaluation of linear pharmacokinetic equations